Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) Director Matthew Shawn Morris sold 88,110 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the completion of the sale, the director owned 76,651 shares of the company’s stock, valued at $1,941,569.83. This trade represents a 53.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Matthew Shawn Morris also recently made the following trade(s):
- On Monday, June 29th, Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock. The shares were sold at an average price of $25.33, for a total transaction of $1,601,159.96.
- On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total transaction of $427,229.04.
- On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The stock was sold at an average price of $24.96, for a total transaction of $25,384.32.
Privia Health Group Stock Performance
Shares of NASDAQ PRVA opened at $25.73 on Wednesday. The business’s 50 day moving average price is $23.25 and its 200-day moving average price is $22.96. Privia Health Group, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $26.51. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 160.82, a PEG ratio of 2.02 and a beta of 0.90.
Analyst Ratings Changes
PRVA has been the subject of several research reports. Barclays lowered their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Weiss Ratings downgraded shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Evercore set a $26.00 price target on Privia Health Group in a report on Wednesday, April 8th. Citigroup dropped their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group reduced their price objective on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Privia Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.
Check Out Our Latest Research Report on PRVA
Hedge Funds Weigh In On Privia Health Group
A number of hedge funds and other institutional investors have recently modified their holdings of PRVA. Bayban purchased a new stake in Privia Health Group during the fourth quarter worth $26,000. Hantz Financial Services Inc. lifted its stake in shares of Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after purchasing an additional 926 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after purchasing an additional 1,351 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Privia Health Group in the 4th quarter valued at about $93,000. 94.48% of the stock is currently owned by institutional investors.
About Privia Health Group
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Further Reading
- Five stocks we like better than Privia Health Group
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
